You are here

Wildflower Store Opening in New York’s Iconic Times Square in November

VANCOUVER, British Columbia, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Wildflower Brands Inc. (CSE: SUN, OTC:WLDFF) (the “Company”) is excited to announce that design work is completed for three prime locations in Manhattan.  Construction is planned to begin this month with the opening targeted for November 2018, in time for the holiday season.

New York has the highest population density of any major city in the United States and is a top global tourist destination.  New Yorkers and the world view the city as trend setting in many areas including health and wellness. These prime retail locations were chosen to give Wildflower maximum exposure to a vast number of people including some of the most active social media professionals in New York.  The Wildflower by Bridges General branded stores will feature Wildflower’s existing online catalog of products as well as in-store only exclusive products designed specifically for the New York market.  Bridges General is a unique retail concept by Wildflower’s partner Retail Worx. The first three locations include: 

  • 11 Times Square at the base of a 40-story office tower housing offices of Microsoft, British Telecom and E*Trade and is located directly across from The New York Times Building.
     
  • 770 Broadway at the base of a 15-story mixed-use commercial office building. This location gives Wildflower products exposure to all the Facebook employees in New York as Facebook currently occupies almost half of the building.  The building also serves as the New York or worldwide headquarters to several major global brands, including Huffington Post, Yahoo, AOL and Tumblr.
     
  • 11 Madison Avenue at the base of a 30-story office tower.  The building is adjacent to the vibrant Madison Square Park and is within steps of many of the neighborhood’s fine restaurants and shopping locations and houses Credit Suisse, Sony and Yelp.

William MacLean, CEO of Wildflower says, “The team has done an incredible job in designing these new Wildflower branded stores.  The construction team is ready and expect to have the renovations completed within weeks, in time for Black Friday, the busiest shopping day of the year, and the rest of the holiday season.  We are thrilled to have such high visibility stores and intend to be the leading CBD brand in New York.”

ABOUT WILDFLOWER BRANDS

Wildflower Brands is a company headquartered in Vancouver building reputable brands and quality products that incorporate the synergistic effects of plants and their extracts.

ABOUT RETAIL WORX

Retail Worx is an innovative private company that is changing the retail landscape by creating meaningful lifestyle experiences for today’s conscious consumers.

On Behalf of the Board of Directors

William MacLean
____________________________________
William MacLean
Director and CEO

Cautionary and Forward-Looking Statements

This news release contains forwardlooking statements and forwardlooking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forwardlooking statements or information. Forwardlooking statements and information are often, but not always, identified by the use of words such as "appear", "seek", "anticipate", "plan", "continue", "estimate", "approximate", "expect", "may", "will", "project", "predict", "potential", "targeting", "intend", "could", "might", "should", "believe", "would" and similar expressions.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forwardlooking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the risks associated with the marijuana industry in general such as operational risks in growing; competition; incorrect assessment of the value and potential benefits of various transactions; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and government regulations. Accordingly, readers should not place undue reliance on the forwardlooking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forwardlooking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forwardlooking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

The Canadian Securities Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this press release.

CONTACT: 400-1505 West 2nd Ave,
Vancouver, B.C., V6Y 3Y4
Tel: (604) 559-0420

www.wildflowerbrands.co
info@wildflowerbrands.co
Tuesday, September 18, 2018 - 08:30

More Headlines

Resorbable Dextenza is the First Intracanalicular Insert for Drug Delivery
Patients with MS Suffered Stroke, Blood Vessel Tearing in Head and Neck After Receiving Drug
First Biosimilar For Adults With CD20-Positive, B-Cell Non-Hodgkin’s Lymphoma
Life-Threatening Side Effect of Drug for Acute Myeloid Leukemia
First Drug for Rare Autoimmune Disorder That Affects Nerve, Muscles Connection
Hope For Patients With Highly Aggressive Form of AML
Oncology Therapy for Adult and Pediatric Tumors With a Neurotrophic Receptor Tyrosine Kinase (NTRK) Gene Fusion
First Hedgehog Pathway Inhibitor Approved for AML in Adults Aged 75 and Older
Gene Therapy Granted Regenerative Medicine, Fast Track Designations